NASDAQ: CTORCitius Oncology Inc Stock
$0.66-0.03 (-4.35%)
Updated Jun 25, 2026
CTOR Price
$0.66
Fair Value Price
$0.00
Market Cap
$61.37M
52 Week Low
$0.49
52 Week High
$6.19
P/E
-1.4x
P/B
1.74x
P/S
11.05x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.61M
Earnings
-$42.51M
Gross Margin
80.1%
Operating Margin
-742.27%
Profit Margin
-757.6%
Debt to Equity
1.86
Operating Cash Flow
-$17M
Beta
-0.11
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CTOR Overview
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CTOR's potential to beat the market
- CTOR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
CTOR
RankedUnranked of 50
RankedUnranked of 50
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $164.18 | A | |
| $41.29 | A | |
| $83.28 | A |
Be the first to know about important CTOR news, forecast changes, insider trades & much more!
CTOR News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CTOR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CTOR ($0.66) is overvalued by 38,648.42% relative to our estimate of its Fair Value price of $0.00 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CTOR ($0.66) is not significantly undervalued (38,648.42%) relative to our estimate of its Fair Value price of $0.00 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CTOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CTOR due diligence checks available for Premium users.
Valuation
CTOR fair value
Fair Value of CTOR stock based on Discounted Cash Flow (DCF)
Price
$0.66
Fair Value
$0.00
Overvalued by
38,648.42%
CTOR ($0.66) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CTOR ($0.66) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CTOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CTOR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.4x
Industry
-4.15x
Market
8.79x
CTOR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.74x
Industry
1.55x
CTOR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CTOR's financial health
Profit margin
Revenue
$1.7M
Net Income
-$26.6M
Profit Margin
-1,596%
CTOR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CTOR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$100.7M
Liabilities
$65.4M
Debt to equity
1.86
CTOR's short-term liabilities ($58.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CTOR's short-term assets ($29.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CTOR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.8M
Investing
-$600.0k
Financing
-$231.2k
CTOR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CTOR vs Pharmaceutical Stocks
Citius Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.